Ophthalmic device company BVI Medical unveiled its new Virtuoso phaco-vitrectomy surgical platform.
The company designed its new dual-function system for both cataract and vitreoretinal procedures. It aims to redefine control and accuracy in ophthalmic surgery with its Virtuoso system. BVI included advanced technologies across fluidics control, vitreoretinal applications, ultrasound delivery and usability.
Altogether, Virtuoso offers a single, high-performance platform with a footprint that optimizes space in the operating room. It addresses the needs of the growing number of ambulatory surgical centers (ASCs) and hospitals seeking flexible, cost-effective options. The system also strengthens BVI’s value proposition by coupling its portfolio of consumables and intraocular lenses (IOLs).
BVI Medical plans to introduce Virtuoso at the upcoming 2025 Global Surgical Ophthalmic Congresses in Europe (ESCRS, Euretina) through targeted promotional activities. It also committed to a prospective, single-center clinical investigation at LMU Klinikum in Munich, Germany. This study seeks to confirm the platform’s safety and effectiveness.
The company plans to begin rolling the system out in select European markets, followed by a global launch subject to market approvals.
“Virtuoso represents a significant leap in surgical technology, bringing efficiency and control to both anterior and posterior segment procedures,” said Shervin Korangy, president and CEO of BVI. “With Virtuoso, we are expanding our presence in the equipment segment of ophthalmology and look forward to watching millions of patients benefit from this technology. The excitement from the ophthalmic community for this much anticipated introduction is palpable.”
